AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Summary
- Numinus shares shot up about 60 per cent in November and over 81 per cent in December to date.
- Genome analysis company Bionano Genomics Inc saw its stocks skyrocket by over 50 per cent on Tuesday.
- The S&P 500 Health Care, up by 10.17 per cent this year, climbed 0.44 per cent on Tuesday, December 29.
Stocks of health-related companies Numinus Wellness Inc (TSXV:NUMI) and Bionano Genomics Inc (NASDAQ: BNGO, BNGO:US) have been trending high on the stock markets. While the progress in the field of COVID-19 vaccines boosted stock performances at large, these two companies posted their own developments recently.
The S&P 500 Health Care, up by 10.17 per cent this year, climbed 0.44 per cent on Tuesday, December 29. Let’s take a closer look at the profiles of Numinus Wellness Inc and Bionano Genomics Inc to understand their recent trend.
Numinus Wellness Inc (TSXV:NUMI) & Bionano Genomics Inc (NASDAQ: BNGO, BNGO:US)
Numinus Wellness Inc, a Canadian psychedelic therapy company, announced closing a bought deal offering worth C$ 17 million on Tuesday. Using the net proceeds generated from this recent financing, the company plans to upgrade its laboratories and clinics for clinical trials, acquire more clinics, expand research and development of medical protocols, as well as use it as general working capital.
The company halted its share trading on Tuesday ahead of the bought deal offering. Stocks of Numinus Wellness, currently trending heavily on the Toronto Stock Exchange Venture (TSXV), post a 10-day average trading volume of 8.14 million.
Numinus stocks, which last traded at C$ 1.25 on the TSXV, debuted on the stock exchange platform earlier this year in May. Since the debut, the scrips climbed over 21 per cents in the last seven months.
The health care stock shot up about 60 per cent in November and over 81 per cent in December to date.
©Kalkine Group Image
Genome analysis company Bionano Genomics Inc saw its stocks skyrocket by over 50 per cent on Tuesday, a day after it announced that its customer, Praxis Genomics, was accredited by the College of American Pathologists (CAP).
Bionano Genomics stocks, currently priced at US$ 1.13, surged about 171 per cent in December to date and nearly 183 per cent in the last six months.
The company posted a massive average share trading volume of over 47 million in the last 10 days and of nearly 20 million in the past month.
